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Inflammatory pathology markers (activated microglia and reactive astrocytes) in early and late
onset Alzheimer disease: a post mortem study
Aims: The association between the pathological features
of AD and dementia is stronger in younger old persons
than in older old persons suggesting that additional fac-
tors are involved in the clinical expression of dementia
in the oldest old. Cumulative data suggests that neu-
roinflammation plays a prominent role in Alzheimer0s
disease (AD) and different studies reported an age-asso-
ciated dysregulation of the neuroimmune system. Con-
sequently, we sought to characterize the pattern of
microglial cell activation and astrogliosis in brain post
mortem tissue of pathologically confirmed cases of early
and late onset AD (EOAD and LOAD) and determine
their relation to age. Methods: Immunohistochemistry
(CD68 and glial fibrillary acidic protein) with morpho-
metric analysis of astroglial profiles in 36 cases of AD
and 28 similarly aged controls. Results: Both EOAD and
LOAD groups had higher microglial scores in CA1,
entorhinal and temporal cortices, and higher astroglial
response in CA1, dentate gyrus, entorhinal and tempo-
ral cortices, compared to aged matched controls. Addi-
tionally, EOAD had higher microglial scores in
subiculum, entorhinal and temporal subcortical white
matter, and LOAD higher astrogliosis in CA2 region.
Conclusions: Overall, we found that the neuroinflamma-
tory pathological markers in late stage AD human tissue
to have a similar pattern in both EOAD and LOAD,
though the severity of the pathological markers in the
younger group was higher. Understanding the age effect
in AD will be important when testing modifying agents
that act on the neuroinflammation.
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Introduction
Alzheimer0s disease (AD) is a chronic neurodegenera-
tive disorder and is the most common cause of demen-
tia. The two major neuropathological hallmarks of the
disease are senile plaques, mainly composed of extracel-
lular deposits of amyloid b (Ab), and neurofibrillary
tangles, consisting of intracellular aggregates of
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aberrantly phosphorylated tau protein. This is accom-
panied by neuronal and synaptic loss, dendritic and
axonal changes and inflammatory reactive lesions
[1,2]. Cumulative data suggest that neuroinflammation
plays a prominent and early role in AD [3–9]. In fact,
neuropathological studies have shown the presence of
a broad variety of inflammation-related proteins (com-
plement factors, acute-phase proteins, proinflammatory
cytokines) and clusters of activated microglia around
amyloid plaques in both transgenic models and AD
subjects [8]. Furthermore, polymorphisms in genes
encoding microglia-specific proteins involved in phago-
cytic and protein degradation pathways increase the
risk of AD [10,11]. Reactive astrocytes also tend to
accumulate around fibrillar amyloid plaques [12] and
similar to microglia, astrocytes release cytokines and
other potentially cytotoxic molecules after exposure to
Ab, thus aggravating the neuroinflammatory response
[9].
The prevalence of AD is strongly associated with
increasing age, and age-related changes in microglia
have been hypothesized to play a prominent role in dis-
ease pathogenesis [13]. Regardless of clinical resem-
blance and neuropathological features, important
differences exist between early and late onset AD
[EOAD (<65 years old) and LOAD (>65 years old)]
patients [14–17]. Taking into account data regarding
the importance of neuroinflammation in the pathogen-
esis of AD, particularly the role of microglia, and the
differences in the neuroimmunological milieu of the
aged brain, it is conceivable that the pattern of neu-
roinflammation associated with AD might differ
between these two groups and contribute to, or
explain, clinical differences [17]. Hoozemans et al. [18]
suggested that an association between neuroinflamma-
tion and AD is much stronger in relatively young
patients compared to older patients (age at death <80
vs. >80 years old). More recently, shortening of micro-
glial cell processes and reduced of coverage of brain
parenchyma with normal ageing and AD has been
reported [19].
In this study, we characterized the distribution of
activated microglia in multiple anatomical areas (hip-
pocampal formation; frontal, temporal, parietal and
occipital cortical grey and subcortical white matter)
and the degree of astrogliosis in selected areas (hip-
pocampal formation and temporal cortical grey and
subcortical white matter), in clinically and
pathologically confirmed AD and non-demented control
cases in relation to age. Our results suggest that overall
there is a similar topographical pattern in pathological
markers of neuroinflammation in both EOAD and
LOAD. However, there are differences in the severity of
microglial scores and astrogliosis when comparing
these two groups with age-matched controls.
Patient and methods
Patients
Fifty-seven cases were investigated. The majority of
cases were obtained from the Manchester Brain Bank
(30 AD and 9 control cases) through appropriate con-
senting procedures for the collection and use of the
human brain tissues. Additional control cases were
obtained from Oxford Brain Bank (14 cases) and from
Queen Square Brain Bank (4 cases), also through
appropriate consenting procedures for the collection
and use of the human brain tissues. Cases were approx-
imately age-matched. The AD cases met the pathologi-
cal criteria for definite AD (‘High’ AD neuropathologic
change) [20]. Cases with associated hippocampal scle-
rosis were excluded. The 18 controls were judged to be
clinically normal and none showed any pathology
beyond that which might be anticipated for age. The
study was approved by the relevant local Brain Bank
Committees under their devolved Generic Tissue Bank
ethics.
Methods
Immunohistochemistry (IHC) IHC staining for CD68
and glial fibrillary acidic protein (GFAP) was performed
using the Ventana OptiView DAB IHC detection kit and
the Ventana BenchMark Ultra processor (Ventana,
Tucson, AZ, USA). Sections of temporal (including
hippocampus and parahippocampal region), frontal,
parietal and occipital cortices were cut at 6 lm
thickness from formalin fixed, paraffin embedded blocks
and mounted on to glass slides. Paraffin tissue sections
were deparaffinized with EZ Prep (Ventana), pre-treated
with heat treatment with Ultra Cell Conditioning
Solution (CC1; Ventana) and the endogenous
peroxidase was inactivated before the incubation with
the CD68 antibody (PG-M1, 1:400; Dako, Glostrup,
Denmark) for 24 min at 36°C and GFAP (Z 0334,
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1:2500; Dako) for 12 min at 36°C. Subsequently, the
slides were incubated with OptiView HQ linker for
8 min, and then with OptiView universal HRP
multimer (Ventana) for a further 8 min at 36°C. Tissue
sections were incubated with OptiView universal DAB
chromogen (Ventana) for 8 min to detect the antigen-
antibody complex and then counterstained with
Haematoxylin II (Ventana).
Similar study methods for IHC were used with Iba1
antibody (Wako Cat. #019-19741, Wako Pure Chemi-
cal Industries, Osaka, Japan) using a series of random
temporal cortical sections across the groups (16 cases).
Microscopic semi-quantitative analysis Microglia—Both
CD68 and Iba1 antibodies mark microglial cells, both
in resting and activated states (Figure 1a,b). Resting
microglia were defined by a small cell body and
ramified processes [21] and activated microglia by their
shortened processes and hypertrophy of cell body [22].
Sections from the different interest regions were
assessed for the presence of immunostained microglial
cells within both the cortical grey and subcortical
white matter at 9 20 magnification. As previously
described [23,24], the frequency and ‘severity’ (in
terms of morphological types, with activated microglial
cells being considered to be more severe than ramified
microglial cells) of CD68-immunostained sections was
assessed according to:
0 = No immunostained cells present.
1 = Very few immunostained cells present, all as rami-
fied microglia.
2 = A moderate number of immunostained cells pre-
sent, mostly ramified but some activated cells present.
3 = Many, diffusely spread, immunostained cells pre-
sent, all as activated microglia.
4 = Many, large clusters of activated microglial cells
present (Figure 2).
Perivascular CD68 immunostained cells (perivascular
macrophages) were discounted for the scoring analysis.
For each section, the cortex and white matter was
scored separately. Additionally, in the temporal block,
hippocampal formation [CA1, CA2/3, dentate gyrus
Figure 1. Ramified (a) and activated (b) microglia cells, as seen in CD68 immunostaining in temporal cortex [a – CONTy case; b – early
onset Alzheimer0s disease (EOAD) case]. Clustering of activated microglial cells within an amyloid plaque (c, EOAD case). Astrocytes
immunoreactive for glial fibrillary acidic protein (GFAP) immunostaining closely associated to an amyloid plaque (d) and dispersed in the
cortex (e). Example of a hippocampal section of an AD case with GFAP immunostaining (f). (d–f, EOAD case). Scale bars: 50 lm (a,c,d),
100 lm (b,e), 1 mm (f). a–c: CD68 immunohistochemistry (PGM1 clone; Dako); d–f: GFAP immunohistochemistry (Z 0334; Dako).
[Colour figure can be viewed at wileyonlinelibrary.com]
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(DG) and subiculum], hippocampal white matter,
entorhinal cortex and entorhinal white matter were
also scored separately.
The assessment of Iba1 scores followed the same pro-
cedures as CD68.
Astrocytes—Astrogliosis is characterized by cellular
hypertrophy with an increase in expression of GFAP
and an abnormal apparent increase in the number of
astrocytes [25]. Sections of the temporal block were
assessed for the presence of astrogliosis within both the
cortical grey and subcortical white matter and
hippocampal formation. The presence and degree of
astrogliosis of GFAP-immunostained sections was
assessed according to:
0 = No GFAP immunostained cells present.
1 = Very few GFAP immunostained cells present with
thinly ramified processes and no cell body hypertrophy.
2 = Moderate number of GFAP immunostained cells
present, some with intense immunoreactive processes
and cell body hypertrophy.
3 = Many, diffusely spread, GFAP immunostained cells
present, all with cell body hypertrophy and intense
immunoreactive processes.
4 = Many GFAP immunostained cells present, all with
cell body hypertrophy and intense immunoreactive pro-
cesses with areas of large clusters of GFAP immunos-
tained cells with these characteristics (Figure 2).
In the white matter, increased numbers of fibroblas-
tic astrocytes were employed for grading (0–3) with
increased GFAP staining with aspects of glial scarring
being considered for grade 4.
All microglial and astrocytes assessments were made
by a single observer (RT), who was blinded to case
diagnostics.
Cell counting procedure An unbiased microscopic
stereological analysis was performed in the subiculum and
entorhinal cortex (five cases per group) and correlated
with the semi-quantitative scales scores for microglia
activation and astrogliosis. Quantification of GFAP+ and
CD68+ cells was performed in accordance with the
following criteria: (i) large cells with increased processes
complexity were counted as GFAP+ cells; and (ii) large
cells with shortened processes were counted as CD68+
cells (activated microglia), respectively. Additionally, a
total count of cells with visible processes (small and thick
or ramified) in CD68 immunohistochemistry assay was
performed. The cells were counted on Visiopharm
Integrator System Software (version 2.12.3.0; Hoersholm,
Denmark), using a motorized microscope (BX-51;
Olympus, Hamburg, Germany) attached to a digital
camera (U-TV1X-2; Olympus), with the 409 oil-
immersion objective. The subiculum and entorhinal cortex
were selected and inside it, two smaller areas were
designated for cell counting. Square probes (50 9 50 lm)
Figure 2. Representative examples of the microglial and astrocytosis assessment according to the scale description. Scale bars: 100 lm
(CD68) and 200 lm [glial fibrillary acidic protein (GFAP)]. CD68 (PGM1 clone; Dako) and GFAP immunohistochemistry (Z 0334; Dako).
[Colour figure can be viewed at wileyonlinelibrary.com]
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were placed randomly over the selected areas, covering
20% of the total defined areas, ensuring unbiased
sampling. The cells within the criteria aforementioned and
inside the probes were counted. All counts were performed
by a single observer (VF) blinded to the diagnosis.
Astrocytes profiles morphological analysis Three-
dimensional reconstructions of representative GFAP+
cells within the subiculum region were made. Cell
reconstruction was performed in accordance with the
following criteria: (i) dendritic tree does not have
truncated processes and (ii) relative isolation from
neighbouring marked cells. According these criteria
and using the Neurolucida software (MBF Bioscience,
Williston, VT, USA) and a motorized microscope
(Axioplan 2; Carl Zeiss, Oberkochen, Germany)
attached to a camera (3CCD Color Video Camera;
Sony, Minato, Tokyo, Japan), the GFAP+ cells were
reconstructed, with the 1009 oil-immersion objective.
The first three GFAP+ cells identified in the region of
interest that complied with the criteria were
reconstructed, per experimental case, and subsequently
analysed by NeuroExplorer Software (MBF Bioscience).
All reconstructions were performed by a single observer
(VF) blinded to diagnosis.
Statistical analysis
Rating data was entered into an Excel spreadsheet and
analysed using Statistical Package for Social Sciences
(SPSS) software (version 22.0), Armonk, NY. A P-value
of <0.05 was considered statistically significant.
Kruskal–Wallis test was performed for analysis. If this
detected any significant differences between the groups,
post hoc testing was performed to identify the groups
between which significant differences existed (Dunn–
Bonferroni). Kendall0s s coefficient was used to assess
correlation between age and microglial scores or
astrogliosis in each group.
Results
Four groups were established (Table 1) based on con-
firmation from pathology (AD vs. controls) and age at
death. In the AD group, a cut-off of ≤ 65 years for
age of onset was used for classification in EOAD and
LOAD. An age at death of 75 years was used in the
control group (CONTy and CONTo) as a cut-off to
match the age at death of the AD groups. Cases were
grouped as EOAD (n = 19), LOAD (n = 11), young
non-demented controls (CONTy) (n = 15) and old non-
demented controls (CONTo) (n = 12). There were no
differences between EOAD and CONTy, and between
LOAD and CONTo in age at death (P = 0.575 and
P = 1.0, respectively; Kruskal–Wallis). EOAD and
LOAD groups differed in the disease duration
(P = 0.016; Kruskal–Wallis), with EOAD cases having
a longer disease duration than LOAD cases (9.8 years
vs. 7.6 years, respectively). The groups were not
homogeneous regarding to gender with over represen-
tation of males in EOAD group (see Table S1 for
detailed pathological and demographic details, and dis-
ease duration per case).
As previously described [23,24], the topographic dis-
tribution of activated microglial cells generally followed
that of the principal pathological changes within the
cortex and hippocampal formation of AD cases, with
activated microglial cells often being clustered within
and around amyloid plaques (Figure 1c). Similarly to
other descriptions, activated microglial cells were also
Table 1. Clinical and pathological status, demographic information and disease duration
Male: female Mean age at death (SD) Interval of age at death Mean age of disease onset (SD) Mean disease duration (SD)
EOAD
n = 19
17M: 2F 66.74 (6.62) 45–73 56.72 (6.11) 9.78 (2.46)
LOAD
n = 11
4M: 7F 82.91 (5.13) 76–89 76.0 (4.59) 7.60 (1.26)
Controls young
n = 15
7M: 8F 59.47 (8.73) 38–71 NA NA
Controls old
n = 12
6M: 6F 83.75 (6.81) 75–95 NA NA
NA, not applicable; EOAD, early onset Alzheimer0s disease; LOAD, late onset AD.
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observed apparently unassociated with amyloid plaques
[26]. In the control cases activated microglial cells were
largely absent in most of the cases, though a few were
occasionally seen in association with rare amyloid
deposits. Ramified microglial cells were commonly seen
in many of these cases. The morphological patterns
were similar with both antibodies, though Iba1 showed
a better definition of the ramified morphology of the
resting microglia (Figure S1). CD68 and Iba1 scores
showed a strong correlation in the same region anal-
ysed (r = 0.659, P < 0.01 in entorhinal cortex;
r = 0.464, P < 0.05 in entorhinal subcortical white
matter, r = 0.782, P < 0.001 in temporal cortex;
r = 0.529, P < 0.05 in temporal subcortical white mat-
ter, Kendall’s s coefficient; Figure S2).
As expected, astrogliosis in the AD group was
more prominent in layers II–III and layer V [27].
Similarly to microglia, we found a dense astrogliosis
both intimately associated with amyloid plaques and
also remote from amyloid plaques [28] (Figure 1d,e).
Most control cases showed rare immunoreactive
astrocytes with long and thin dendritic arborizations
without laminar pattern. Figure 3 shows repre-
sentative examples of CD68 and GFAP immunostain-
ing in the entorhinal region in the four different
groups.
Figure 3. Representative examples of CD68 and glial fibrillary acidic protein (GFAP) immunostaining in cases of the different groups
studied. Scale bar: 50 lm. EC, entorhinal cortex; EWM, entorhinal white matter. CD68 (PGM1 clone; Dako) and GFAP
immunohistochemistry (Z 0334; Dako). [Colour figure can be viewed at wileyonlinelibrary.com]
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Semi-quantitative scores for microglial cell counts
showed a strong correlation with stereological counting
of activated microglia in the subiculum (r = 0.629,
P < 0.001) and entorhinal cortex (r = 0.771,
P < 0.001). Similarly, semi-quantitative scores for
astrogliosis showed a strong correlation with stereologi-
cal counting of GFAP positive astrocytes in subiculum
(r = 0.629, P < 0.001) and entorhinal cortex
(r = 0.650, P < 0.01) (Figure S3). Interestingly, in the
subiculum stereological counting of microglia corre-
lated with GFAP (stereological counting and semi-
quantitative scale) only when activated microglia were
considered (r = 0.386, P < 0.05 and r = 0.471,
P < 0.05, respectively).
Microglial scores based on the patterns of CD68
staining
Hippocampal formation Microglial cell scores were
significantly different between EOAD, LOAD, CONTy and
CONTo groups for the CA1 region of hippocampus
(P = 0.001), subiculum (P = 0.001) and hippocampal
white matter (P = 0.022). Post hoc testing showed that
in the CA1 region the AD groups differed from their aged
Figure 4. Comparison of microglia scores between groups in different regions (a - h) and correlation between microglia severity score in
occipital cortex and age at death (i). a - h: *P < 0.05 and **P < 0.01, Kruskal–Wallis. Y axes represent semi-quantitative scale mean
and bars represent SE. i: r = 0.322; p < 0.05, Kendall’s t coefficient
© 2017 British Neuropathological Society NAN 2018; 44: 298–313
304 R. Taipa et al.
matched controls (EOAD vs. CONTy and LOAD vs.
CONTo, P = 0.024 and P = 0.043, respectively).
Additionally, the LOAD group displayed higher
microglial scores than the CONTy (P = 0.012)
(Figure 4a). In the subiculum, only the EOAD had
higher microglial scores than their aged matched control
group (CONTy) (P = 0.001) (Figure 4b). Post hoc testing
in the hippocampal white matter did not show
differences between any of the groups (Figure 4c). There
were no differences between EOAD and LOAD in any of
the regions studies. Similarly, no differences were found
between CONTy and CONTo groups.
Cortex and subcortical white matter Microglial cell
scores were significantly different between EOAD,
LOAD, CONTy and CONTo groups for entorhinal cortex
and entorhinal subcortical white matter (P < 0.001
and P = 0.005, respectively) temporal cortex and
temporal subcortical white matter (P < 0.001 and
P = 0.048, respectively) and occipital cortex
(P = 0.037). There was no significant effect of disease
status in the other regions studied (frontal cortex and
white matter, parietal cortex and white matter,
occipital white matter).
Post hoc testing showed that both AD groups had
higher microglial scores than their aged matched con-
trol groups in entorhinal cortex (P = 0.002 for EOAD
vs. CONTy and P = 0.018 for LOAD vs. CONTo). They
both differed from the non-age matched control group
(EOAD vs. CONTo, P = 0.026; LOAD vs. CONTy,
P = 0.002) (Figure 4d). In the entorhinal subcortical
white matter, only the EOAD had higher microglia
scores compared to the age matched control group
(P = 0.006). The LOAD did not differ in this region
from either of the control groups (Figure 4e).
In the temporal cortex, both AD groups had higher
microglial scores than their aged matched control
groups (P = 0.001 for EOAD vs. CONTy and P = 0.028
for LOAD vs. CONTo). Similar to the entorhinal region,
they also both differed from the non-age matched con-
trol group (EOAD vs. CONTo, P = 0.003; LOAD vs.
CONTy, P = 0.020) (Figure 4f). Similar to the entorhi-
nal region, in the temporal subcortical white matter,
only the EOAD showed higher microglial scores com-
pared to their control group (EOAD vs. CONT y,
P = 0.045) (Figure 4g). Post hoc testing did not show
differences between any of the groups in the occipital
cortex (Figure 4h).
Correlations between microglial cell activation with age of
onset, age at death and disease duration In the AD
group, there was a positive correlation between age at
death and occipital cortex microglial scores (r = 0.322,
P = 0.025) (Figure 4i). In addition, in the AD group
there was a positive correlation between disease
duration and the microglial scores of frontal and
occipital white matter (r = 0.375, P = 0.019;
r = 0.318, P = 0.044, respectively).
In the control group, there was no correlation
between age at death and microglial scores.
Astrogliosis based on the patterns of GFAP staining
Hippocampal formation Astrogliosis scores were
significantly different between EOAD, LOAD, CONTy
and CONTo groups in all hippocampal regions assessed,
namely CA1 (P < 0.001), CA2/3 (P = 0.001), CA4
(P = 0.012), DG (P < 0.001), subiculum (P < 0.001)
and hippocampal white matter (P = 0.002).
Post hoc testing showed that in the CA1 region, both
AD groups had higher astrogliosis scores than their aged
matched controls (EOAD vs. CONTy, P < 0.001 and
LOAD vs. CONTo, P = 0.007) and non-aged matched
control group (EOAD vs. CONTo, P = 0.013 and LOAD
vs. CONTy, P < 0.001) (Figure 5a). Remarkably, in
CA2/CA3 region only the LOAD group had higher scores
compared to both their age matched control (P = 0.002)
and non-aged matched control (P = 0.009) (Figure 5b).
In CA4 post hoc testing did not show differences between
any of the groups (Figure 5c). In the DG and subiculum
both groups differed from their age matched control
(EOAD vs. CONTy, P = 0.003 and LOAD vs. CONTo,
P = 0.008 for DG; EOAD vs. CONTy, P = 0.001 and
LOAD vs. CONTo, P = 0.001 for subiculum) and non-
age matched control (EOAD vs. CONTo, P = 0.005 and
LOAD vs. CONTy, P = 0.005 for DG; EOAD vs. CONTo,
P = 0.001 and LOAD vs. CONTy, P = 0.001 for subicu-
lum) (Figure 5d,e). In the hippocampal white matter,
there were differences between EOAD group and CONTy,
with higher scores in the former group (P = 0.003).
LOAD showed higher scores only when compared to the
non-aged matched control (LOAD vs. CONTy,
P < 0.001).
Entorhinal and temporal neocortical regions Astroglial
scores were significantly different between EOAD,
LOAD, CONTy and CONTo groups for entorhinal cortex
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and temporal cortex (P < 0.001 for both) and
entorhinal subcortical white matter (P = 0.022). There
was no significant effect of disease status in the
temporal cortex white matter.
Post hoc testing showed that in the entorhinal and
temporal cortices, both groups differed from their age
matched control (EOAD vs. CONTy, P < 0.001 and
LOAD vs. CONTo, P = 0.004 for entorhinal cortex;
EOAD vs. CONTy, P < 0.001 and LOAD vs. CONTo,
P = 0.021 for temporal cortex) and non-age matched
control (EOAD vs. CONTo, P < 0.001; LOAD vs.
CONTy, P = 0.001 for entorhinal cortex; EOAD vs.
CONTo, P < 0.001 and LOAD vs. CONTy, P = 0.025
for temporal cortex). In the entorhinal subcortical
white matter, post hoc testing did not show differences
between any of the groups (Figure 5f–i).
Correlations between and astrogliosis with age of onset, age
at death and disease duration In the AD group, there
was a positive correlation between age at death and
astrogliosis scores in the hippocampal white matter
(r = 0.393, P = 0.039) and entorhinal cortex
Figure 5. Comparison of astroglial scores between groups in different regions (a - i). *P < 0.05, **P < 0.01 and ***P < 0.001, Kruskal–
Wallis. Y axes represent semi-quantitative scale mean and bars represent SE.
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subcortical white matter (r = 0.392, P = 0.043). There
was no correlation with other regions or with age of
onset or disease duration.
In the control group, there was a positive correlation
with age at death and hippocampal white matter
(r = 0.450, P = 0.006). There was no correlation with
other regions studied.
Astroglial morphological profiles
Forty cases showed sufficient quality of immunohisto-
chemistry staining to permit morphological analysis
(13 EOAD, 5 LOAD, 13 CONTy and 9 CONTo). There
were no significant differences in surface, volume or
cell body area and perimeter of astrocytes in the
subiculum between the different groups. Similarly,
when considered together there were no differences
between the AD group (EOAD plus LOAD) and controls
(Figure 6).
Discussion
There is clinical and experimental evidence that the
aged brain is characterized by a shift towards a pro-
inflammatory state [29,30]. This age-associated neu-
roinflammation is characterized by an upregulated
Figure 6. Bar graphs representing glial fibrillary acidic protein surface, volume, and cell body area of astrocytes in subiculum (a - c; Y
axes represent cell count density in lm2). Representative examples of astrocyte profiles reconstructions in the bottom panel. Variability
within groups is depicted by astrocytes with higher and lower complexity of processes (upper and lower examples within groups
respectively). Scale bar: 10 lm
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astrocyte and microglial cell reactivity in association
with increased levels of circulating cytokines such as
TNF-alfa, IL-1beta and IFN-gamma [31,32]. AD is an
age-related disease and there is compelling data show-
ing that the activation of the immune system accompa-
nies and contributes to the pathogenesis of this
disorder [33,34]. There is still ongoing controversy
about the role of neuroinflammation in AD, namely the
possibility of a disease-initiating mechanism in neu-
rodegenerative disorders [34]. Large numbers of studies
have investigated the microglia and astrocyte response
to Ab, mainly using in vitro culture approaches and/or
animal models for tissue immunostaining. However,
and as an example, the study of AD degenerative pro-
cess involving microglial cells in the AD hippocampus
of human post mortem samples is not mimicked by Ab
models, and only partially so by tau animal models
[26]. Human post mortem studies are relatively few
and, despite their inherent difficulties, their major value
is the study of the disease itself and, thus, helping in
bridging the vast knowledge obtained by disease animal
models.
This study explores the severity of neuroinflamma-
tion pathology markers (microglia activation and
astrogliosis) in AD pathologically proven cases (Braak
stage V–VI) and controls in relation to their age. Two
populations were defined according to the age onset/
age of death to mimic clinical common distinction
between EOAD and LOAD. Our results show that over-
all the pattern of neuroinflammation is similar between
both age AD groups. In fact, we did not find the differ-
ences reported by Hoozemans et al. [18] claiming a
stronger association with neuroinflammation in rela-
tively young AD cases compared to old AD cases. A
major difference between the two studies relates to the
pathological criteria for inclusion: while in the present
study Braak stage V or VI was a pathological criterion
for inclusion, in the Hoozemans et al. work different
Braak stages were included, namely with some of old
AD cases classified as Braak stage II and all of young
cases Braak stage V or VI. In fact, the purpose of this
study was to assess the degree of neuroinflammation
according to age in AD, and not an association with
AD pathological severity.
Although we did not find any differences in direct
comparison between EOAD and LOAD cases, there were
differences in the magnitude of the neuroinflammatory
markers studied when compared to the respective aged
matched non-demented controls. Regarding microglial
activation, there were higher microglial activation
scores in EOAD when compared to aged matched con-
trols, particularly in white matter (entorhinal and tem-
poral regions). The simplest and most plausible
explanation is that age-associated increases in micro-
glial expression attenuate local differences in the older
group [24]. However, it is worth highlighting that
imaging studies of AD cases with a similar group anal-
ysis (EOAD vs. age matched controls and LOAD vs. age
matched controls) have reported greater WM atrophy
in EOAD than LOAD [35,36], probably reflecting a
more aggressive form of the disease [35]. Recently,
McAleese et al. [37] showed that white matter lesions
differ between AD and non-demented individuals at
pathological and biochemical levels, suggesting that the
pathogenesis is associated with degenerative axonal
changes, these probably occurring secondary to cortical
AD-pathology. In our study, despite similar AD neocor-
tical pathology severity (Braak stage V or VI) we found
a greater activation of microglia in the white matter of
entorhinal and temporal regions in EOAD, suggesting
that age and microglia response can influence the role
of AD pathology in the pathogenesis of white matter
lesions. Curiously, there was a positive correlation with
age at death and microglia activation in the occipital
cortex in AD cases. This finding seems to contradict the
regional differences reported between EOAD and LOAD,
where older patients tend to have a more circumscribed
disorder affecting the medial temporal lobe regions,
whereas EOAD have broader neocortical involvement
[17]. Functional imaging studies have shown a
predilection for temporo-parietal-occipital association
areas in EOAD vs. medial temporal cortex susceptibility
in LOAD [38,39] and, recently, it was shown that with
a comparable burden of fibrillar amyloid-b (as mea-
sured by Pittsburgh compound-B PET), there was
greater posterior cortical hypometabolism in EOAD.
This study focused on late stage AD pathology, thus
probably obscuring differences that are typically
reported in early disease stages [40]. However, it is
interesting that microglial cell activation in the occipi-
tal cortex increases in relation to age in this AD post
mortem sample, highlighting the complex relation
between pathological findings and level of function.
Serrano-Pozo [41] reported no differences in age at
death in microglial cell activation in the temporal cor-
tex of AD patients, but did not analyse other regions.
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We did not found a correlation with age and microglial
scores in the control group. Certainly, complementary
morphometric studies or studies directed towards func-
tional microglial analysis would be of importance in
order to interpret the current findings.
While the role of microglia in the neuroinflammatory
response in AD is well established [34], several studies
indicate that astrocyte-mediated inflammatory process
also contribute to neurodegeneration in AD [42].
Enhanced expression of GFAP and astrocyte hypertro-
phy have been identified in post mortem tissue from AD
cases [27,43,44]. As expected, we found a higher
astrocyte response in AD cases when compared to aged
matched control cases in the majority of the regions
studied. Similar to the microglial findings in this study,
the pattern of response did not differ between EOAD to
LOAD. In astrocyte response, at least in the temporal
region, there are no significant age-associated changes
in GFAP astrocyte expression to attenuate the differ-
ences in astrocyte response pattern in AD. There is lim-
ited knowledge about ageing of astroglia and data
available are controversial. In human post mortem tis-
sue analysis there was no significant changes in astro-
glial cell counts between old and young adult brains
[45,46]. In old rodents, an increase, a decrease and no
change in the number of GFAP positive astroglial cells
have been reported [47]. Interestingly, in the CA2/3
area of the hippocampal formation, we found signifi-
cant differences in the LOAD group when compared to
control groups. It is worth highlighting that the CA2/3
region is generally considered more resistant to AD
pathology, leading us to speculate that the astrocyte
reaction may be linked to other underlying mecha-
nisms, which reinforces the importance of possible vari-
ations in pathology patterns that are associated with
increasing age. Regarding astrocytes, age-dependent
changes in morphology were also reported in rodents,
with apparent significant increase volumes in neocortex
(primary and secondary somatosensory cortex) and
hippocampus (astrocytes from CA3 stratum molecular
region) [48]. These findings were also reported to be
region-specific, with GFAP-positive astroglial profiles
increased in the CA1 region and lower in the entorhi-
nal cortex [49]. In transgenic AD animals studies,
astrocyte atrophy in both hippocampus (CA1 and DG)
[50] and entorhinal cortex was reported [51]. While
astroglial atrophy appears as a generalized process, the
astrocytes that surround plaques were hypertrophic
with increased surface and volume of GFAP-immunos-
tained profiles [50]. All these findings must be inter-
preted with caution, taken into account the probable
region-specific morphological changes associated with
age and, particularly in AD mouse models, several
pathological features of AD pathology are missing. Sur-
prisingly, we did not find any differences between AD
and controls in the astroglial profiles (surface, volume
and soma perimeter and area) despite the higher astro-
glial scores found in the subiculum. The subiculum is
the major output structure of the hippocampus [52]
and is severely affected by AD pathology. We expected
to find differences in the morphological analysis
between AD and control cases in this region but the
analysis did not prove it. There was also no correlation
with age at death and any of the morphological param-
eters studied in the control group. To the best of our
knowledge, there are no human tissue studies in age-
ing or AD that have addressed this issue previously.
Some data support the concept that reactive astrocytes
show hypertrophy of their intermediate filament-rich
main cellular processes but do not extend to occupy a
greater volume of tissue than nonreactive astrocytes
[53,54]. It is also possible that, similar as reported in
animal models [49], there are region-specific astroglial
changes in human ageing and AD. Additionally, the
analysis of astrocyte morphology in relation to proxim-
ity of AD pathology (Ab and tau) could also be infor-
mative [50]. Nevertheless, our (negative) findings
remind us that we need to translate carefully the find-
ings of AD animal models to human tissue analysis.
This work has methodological limitations. We used a
semi-quantitative scale for the assessment of the pathol-
ogy, which has limitations when compared to stereol-
ogy-based quantitative methods. However, we achieved
a strong correlation between unbiased stereological
counting performed in two regions and the semi-quanti-
tative grading. Furthermore, there is recent data suggest-
ing that the increase in glia in the AD brain is due to a
phenotypic change in existing resting glial cells and not
due to glial cell proliferation per se [41]. The assessment
of microglia by present methods allowed us to quantify
microglia activation rather than total microglia
immunohistochemistry intensity ‘signal’. Further studies
using different methods are needed to replicate and
extend these findings, and additional inflammatory
markers can be added in order to better understand
inflammatory process associated with AD pathology.
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Additionally, the understanding of neuroinflammation
in AD warrants further study of the consequences of
alterations in microglial cell and astrocyte morphology
with respect to phenotype and function [34]. Finally,
taken into account the higher risk of developing AD [55]
and potential stronger inflammatory dysregulation in
woman [56], it would be important to explore gender dif-
ferences in AD associated inflammation and ageing.
Conclusion
Understanding the delicate balance between age of
onset and AD pathophysiology will be important to
understand the effect of interventions in dementia. Tak-
ing into account the cumulative data regarding neu-
roinflammatory changes associated with ageing, these
differences must be addressed when modifying agents
that act on the neuroinflammatory system are tested
[17]. In the present study, we have shown that, over-
all, the neuroinflammatory pathological markers in late
stage AD human tissue have a similar pattern at differ-
ent ages. However, when compared to aged matched
controls, the magnitude of the pathological markers in
the younger AD group becomes more evident. The
association between the pathological features of AD
and dementia is stronger in younger old persons
(75 years) than in older old persons (95 years), sug-
gesting that additional factors are involved in the clini-
cal expression of dementia in the oldest old [57].
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